Literature DB >> 27391460

High Relative Expression of Pannexin 3 (PANX3) in an Axillary Sweat Gland Carcinoma With Osteosarcomatous Transformation.

Ryan C Romano1, Jerad M Gardner, Sara C Shalin, Roopa Ram, Rang Govindarajan, Corey O Montgomery, Jasen H Gilley, Richard W Nicholas.   

Abstract

Primary cutaneous sweat gland carcinomas (SGCs) are rare tumors that commonly involve axillae, have a high local recurrence rate, and rarely show sarcomatoid transformation. A 68-year-old man presented with rapid enlargement of a previously stable, asymptomatic pea-sized nodule in the left axilla. Initial excision (with positive surgical margins) at another institution showed characteristic histologic features of a high-grade osteosarcoma and molecular analysis using a 92-gene real-time quantitative reverse transcription-polymerase chain reaction assay confirmed a diagnosis of osteosarcoma with 96% certainty. Notably, the molecular assay demonstrated consistently high relative expression of pannexin 3 (PANX3), a gene involved in normal osteoblast differentiation which, when highly expressed, strongly predicts osteosarcoma per the assay's algorithm. However, on further histologic review, the tumor also contained focal cystic areas, nests, and ducts composed of malignant epithelial cells reminiscent of SGC; these areas directly transitioned into the osteosarcomatous component and were strongly positive for pancytokeratin, CK7, and p63. Within 2 weeks, the lesion recurred and grew rapidly, prompting complete resection, histologic sections of which showed high-grade osteosarcoma without residual epithelial elements. This is the fifth report, to our knowledge, of osteosarcomatous transformation in a SGC, and the only report to date including molecular data. This case demonstrates that osteosarcoma arising from a SGC has a similar molecular profile to de novo primary osteosarcoma of bone. It also emphasizes the importance of histopathologic findings as the established diagnostic gold standard and the need to interpret molecular results within the clinical context.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27391460     DOI: 10.1097/DAD.0000000000000583

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  4 in total

1.  MicroRNA-431-5p Inhibits the Tumorigenesis of Osteosarcoma Through Targeting PANX3.

Authors:  Shengliang Sun; Lei Fu; Gen Wang; Jianli Wang; Liping Xu
Journal:  Cancer Manag Res       Date:  2020-09-08       Impact factor: 3.989

2.  Identification of Pannexin 2 as a Novel Marker Correlating with Ferroptosis and Malignant Phenotypes of Prostate Cancer Cells.

Authors:  Duwu Liao; Guang Yang; Yuan Yang; Xueyong Tang; Haixia Huang; Jichun Shao; Qi Pan
Journal:  Onco Targets Ther       Date:  2020-05-19       Impact factor: 4.147

Review 3.  Pannexin 3 channels in health and disease.

Authors:  Brooke L O'Donnell; Silvia Penuela
Journal:  Purinergic Signal       Date:  2021-07-12       Impact factor: 3.765

Review 4.  Connexins and Pannexins: Important Players in Tumorigenesis, Metastasis and Potential Therapeutics.

Authors:  Sheila V Graham; Jean X Jiang; Marc Mesnil
Journal:  Int J Mol Sci       Date:  2018-06-01       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.